AER 1455936 is a spontaneous case, received on 27/Aug/2014 from a physician via a company representative and
concerns a female patient of unspecified age who died due to CNS manifestations (progressive multifocal 
leukoencephalopathy-PML) while being treated with rituximab (Mabthera).
No medical history, concurrent conditions, or past drugs were reported. 
On an unspecified date, the patient started rituximab therapy (dose, route, form and frequency were not provided) 
for non-hodgkin lymphoma. After completing two cycles of chemotherapy, she developed CNS manifestations 
symptoms for 2 weeks that included: loss of hearing, disturbance in vision and legs weakness. The reporter 
mentioned that the above symptoms concluded that this was PML. The physician stopped the treatment after she 
developed the symptoms and the patient died after two weeks. It was not reported whether an autopsy was 
performed or not.
Print Time: 24-MAY-2016 07:56 AM If a field is blank, there is no data for that field Page 279 of 570
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
At the time of death, the fatal event CNS manifestations (progressive multifocal leukoencephalopathy-PML) was 
persisting.
The reporter did not assess the causality for CNS manifestations (progressive multifocal leukoencephalopathy-
PML) with rituximab.
No further information was provided.
Additional information was received on 31/Aug/2014. The following information was added to the case: the outcome
of fatal event PML was updated as not recovered (previously not reported).